Santhera Pharmaceuticals

Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company engaged in the development and commercialization of innovative treatments for rare neuromuscular and pulmonary diseases, with a strong focus on conditions that have high unmet medical needs. The company is advancing a portfolio aimed at treating Duchenne muscular dystrophy (DMD), which includes late-stage candidates such as Puldysa (idebenone) and vamorolone, designed for patients regardless of their specific mutations or disease stages. Additionally, Santhera is developing lonodelestat (POL6014) for cystic fibrosis and other neutrophilic pulmonary diseases, as well as exploring gene therapy approaches for congenital muscular dystrophies. The company also out-licenses rights to its approved product Raxone (idebenone) for Leber's hereditary optic neuropathy in regions outside North America. Santhera collaborates with research institutions like Cold Spring Harbor Laboratory to investigate potential therapeutic applications of its products, including for COVID-19-related respiratory issues. Headquartered in Pratteln, Switzerland, the company primarily generates its revenue from the European Union.